Revvity is a provider of health science solutions, technologies, and services organized into two segments: Life Sciences and Diagnostics. The Life Sciences segment offers reagents, instruments, software, and services supporting drug discovery and development workflows, including cell, gene, and protein research, with customers spanning pharmaceutical and biotech companies, contract research organizations, and academic and government institutions. The Diagnostics segment covers screening, detection, and diagnosis applications.
Headquartered in Waltham, Massachusetts, Revvity markets products and services in more than 160 countries and employed approximately 11,000 people as of December 2025. The company's strategy focuses on broadening offerings through internal R&D and acquisitions, advancing AI to strengthen differentiated capabilities, and pursuing growth in translational multi-omics, biomarker identification, imaging, and informatics. The company is listed on the NYSE under the symbol RVTY and is a component of the S&P 500.
Life Sciences 50% · Diagnostics 50%
business segments · FY2025 (ended Dec 2025) · share of tagged segment revenue (10-K XBRL, as filed)
